

## Instructions to Authors

### ABOUT JASN

JASN publishes highly competitive original manuscripts, brief reviews, and special articles in areas of basic and clinical science relevant to the broad discipline of nephrology. Subject matter appropriate for JASN includes, but is not restricted to, the following: cell biology; developmental biology; genetics; cell and transport physiology; hemodynamics and vascular regulation; immunology and pathology; pathophysiology of renal disease and progression; mineral metabolism and bone disease; clinical nephrology, epidemiology, and outcomes; dialysis; and transplantation. The editors encourage only the submission of meritorious research that will communicate important advances in the field of nephrology. Please read all sections below before submitting a manuscript.

### REVIEW PROCESS AND DECISIONS

It is the policy of JASN to expedite manuscript review. Because of the large number of manuscripts received and the intense competition for publishing the very best work, many manuscripts will have to be returned without review. Manuscripts judged to fall below the top 30% of manuscripts submitted to the JASN, or that fail to satisfy technical requirements, will be returned to the authors without review. We encourage authors to provide a detailed cover letter outlining the major finding and its level of interest to and beyond the field. We ask that reviewers return their comments within 2 weeks. From the manuscripts that meet the high standards for review, anticipate that the editors will accept approximately 50% for publication. JASN accepts no responsibility for manuscript files that are lost or destroyed through electronic or computer problems. For publication purposes, JASN reserves the right to modify the title and abstract with the final approval of the authors.

### MANUSCRIPT TYPES

**Brief Communications** are articles that report a research result of great importance. The content of the article is less substantial than a regular article. Brief Communications are limited to 1500 words, excluding the abstract, concise methods, references, and figure legends, and are not divided by headings to avoid redundancy. This format begins with an abstract followed by the body of the letter summarizing the background, rationale, main results, and implications. The order of the submitted manuscript should be as follows: title page, abstract (200 words or less), integrated introduction, results, and discussion as an orderly letter, followed by concise methods, acknowledgments, statement of competing financial interests, references (limited to 30), figure legends, and tables. Complete methods, providing sufficient detail to allow

replication of the study, must be provided as supplemental information to be published online with the manuscript at the time of publication. Additional supplemental material, such as figures and tables, may be submitted with the manuscript or requested by the reviewer. The title page should include title, authors (first and last names) and affiliations (including division and/or department as applicable), running title (no more than 30 characters), separate word count for abstract and text, and the corresponding author's address, phone, fax, and email information. Abstracts should be written for easy reading with no abbreviations, but should tell a complete story using data as needed. Abstracts in JASN are unstructured, but are expected to cover relevant background, major methodology, major conclusions, and implications. Brief Communications should have no more than four display items (figures and tables); supplemental data can be submitted and will be archived with the published manuscript on the JASN website.

**Original Articles** are traditional full-length manuscripts of 3000 words or less (excluding title page, methods, figure legends, tables, and references) that address an important research question with a thoughtful and clever experimental design. The order of the submitted manuscript should be as follows: title page, abstract (250 words or less), introduction, results, discussion, concise methods, acknowledgments, statement of competing financial interests, references, figure legends, and tables. Complete methods, providing sufficient detail to allow replication of the study, must be provided as supplemental information to be published online with the manuscript at the time of publication. Supplemental material that is of interest to the readership, such as additional figures or tables, is welcome and will be posted online. If you submit supplemental files that may only be posted online, upload one PDF file that contains all of the supplemental information. Supplemental information is not composed, enhanced or manipulated after submission. It is simply provided and uploaded the way it is submitted. The title page should include title, authors (first and last names) and affiliations (including division and/or department as applicable), running title (no more than 30 characters), separate word count for abstract and text, and the corresponding author's address, phone, fax, and email information. Abstracts should be written for easy reading with no abbreviations, but should tell a complete story covering relevant background, major methodology, major conclusions, and implications, using data as needed. **Meta-analysis articles** are works that combine and contrast results from various studies on a clinical or laboratory topic, following standard or innovative methodology of meta-analysis. They should be submitted in the same format as an Original Article.

**Perspectives** address issues in nephrology and related fields that are important, timely, or controversial. They are appealing and stimulating, and may challenge dogma or present a distinctive point of view. Perspectives may deal with any aspect within the broad compass of nephrology, from basic science to public policy. Perspectives may be submitted for consideration for publication without an invitation, or may be solicited by the Editors. Perspectives must have 1000 words or less, 10 references or less, and no Abstract, and preferably include one figure and/or 1 table. The order of the submitted manuscript should be as follows: title page, integrated discussion, acknowledgments including disclosure of financial interests, references, figure legend and table. The title page should include title, authors and affiliations, running title (no more than 30 characters), and the corresponding author's address, phone, fax, and e-mail information. Manuscripts submitted under the Perspectives category will be subjected to peer review at the discretion of the editors.

**Brief Reviews or Special Articles** are invited manuscripts of approximately 3000 words or less (excluding title page, figure legends, tables, and references) that are of interest to the readership. The editor solicits these reviews. The order of the submitted manuscript should be as follows: title page, abstract (200 words or less), integrated discussion, acknowledgments including disclosure of financial interests, references, figure legends, and tables. The title page should include title, authors and affiliations, running title (no more than 30 characters), separate word count for abstract and text, and the corresponding author's address, phone, fax, and email information. Abstracts should be written for easy reading with no abbreviations.

**Editorials, Occasional Observations, and JASN Debates** are invited manuscripts of approximately 1000–1500 words that are related to published material, raise challenging questions, or explore controversies. The editor solicits such opinion pieces. The order of the submitted manuscript should be as follows: title page, integrated discussion, acknowledgments including disclosure of financial interests, and references; no figures or tables. The title page should include title, authors and affiliations, running title (no more than 30 characters), word count for text, and the corresponding author's address, phone, fax, and email information.

**Clinical Commentaries** are invited manuscripts of approximately 1500 words or less (excluding title page, figure legends, tables, and 15 references) that are solicited by the editor. These manuscripts reflect on current published work, controversies in renal medicine, or updates on clinical care. The order of the submitted manuscript should be as follows: title page, abstract (100 words or less), integrated discussion, acknowledgments including disclosure of financial interests, references, figure legends, and tables. The title page should include title, authors and affiliations, running title (no more than 30 characters), separate word count for abstract and text, and the corresponding author's address, phone, fax, and e-mail information. Abstracts should be written for easy reading with no abbreviations.

**Science in Renal Medicine** is an educational section reviewing the modern understanding behind physiologic and pathophysiologic mechanisms in nephrology by concisely explaining a “unique concept” to the reader. Manuscripts are solicited by the editor and should be 1500 words or less (excluding title page, figure legends, tables, one two-panel figure, and 15 references). The order of the submitted manuscript should be as follows: title page, abstract (100 words or less), integrated discussion, acknowledgments, references, figure legends, and tables. The title page should include title, authors and affiliations, running title (no more than 30 characters), separate word count for abstract and text, and the corresponding author's address, phone, fax, and email information. Abstracts should be written for easy reading with no abbreviations.

**Renal Biopsy with New Insights** Authors may submit a clinical case or case series for consideration for publication by JASN that highlights and is based on findings on renal biopsy, but should also have one or more novel features that pertain to any of the following: 1) new genetic mutation or abnormality; 2) new pathogenetic insight/finding; 3) pathologic feature/finding that uncovers previously unrecognized aspects of the disease; 4) new pathophysiologic insight/finding; or 5) novel therapeutic insight or previously unrecognized therapeutic responsivity that is documented and calls attention to a new therapeutic approach. Manuscripts are 1500 words or less (excluding title page, figure legends, tables, and approximately 15 references). The renal biopsy should be highlighted by a figure depicting light microscopy, immunofluorescence, and electron microscopy. Additional, relevant *in vivo* or *in vitro* data based on human tissue/cells that bring out the novel findings of this type of case may also be included as a figure. The total number of figures should be limited to four. Pithiness is a virtue, as the writing style must be welcoming to readers not readily familiar with your topic. The order of the submitted manuscript should be as follows: title page, abstract (200 words or less), integrated introduction, results, and discussion, concise methods, acknowledgments, references, and figure legends. The title page should include title, authors and affiliations, running title (no more than 30 characters), separate word count for abstract and text, and the corresponding author's address, phone, fax, and email information. Abstracts should be written for easy reading with no abbreviations. Submitted manuscripts will undergo initial editorial assessment and those adjudged to fall within the top 30% will undergo peer review.

## POLICIES

**Embargo Policy:** All information regarding the content and publication date of accepted manuscripts is strictly confidential. Information contained in or about accepted articles may not appear in print, on radio or television, or in electronic form, or be released by the news media, until after 5 pm ET on the day the article appears in the Publish-before-Print page on the JASN website (JASN Express) or on the day the published version of JASN is mailed, whichever comes first. This policy is not meant to inhibit the presentation of the work to

or its discussion among other researchers. For information about publication dates for specific articles, please call Bob Henkel at 202-557-8360 or email [bhenkel@asn-online.org](mailto:bhenkel@asn-online.org).

**Access:** The American Society of Nephrology recognizes and strongly supports the efforts of sponsoring agencies and institutions to increase access to the research that they fund. *JASN* submits, on behalf of its authors, all articles directly to PubMed Central, where they will be freely available within 12 months of publication. In addition, in response to the requirement of some funding agencies for the research that they fund to be freely available immediately upon publication and their willingness to cover the costs associated with doing so, *JASN* offers the Author Choice program (see AUTHOR CHOICE), where, for an additional fee, articles are made freely available immediately upon publication. In addition, authors are encouraged to archive their version of the manuscript in their institution's repositories (as well as on their personal websites). Authors should cite the publication reference and doi number on any deposited version, and provide a link from it to the published article on the *JASN* website. *JASN* articles are also freely available to researchers in developing countries through the Health InterNetwork Access to Research Initiative (HINARI).

**Transfer of Copyright:** The American Society of Nephrology requires authors of original research papers to assign copyright of their published contributions. *JASN*'s author copyright license form (<http://mc.manuscriptcentral.com/jasn>) provides details of the policy. After submission of an article, each author will receive an email with a link to a copyright form. Each author will need to sign and date the form and submit electronically. This is done all through Manuscript Central and will guarantee that each author understands and consents to our publication policy.

**Duplicate Submission/Redundant Publication:** All manuscripts submitted to *JASN* must include a statement in the cover letter indicating that neither the manuscript nor any significant part of it is under consideration for publication elsewhere or has appeared elsewhere in a manner that could be construed as a prior or duplicate publication of the same, or very similar, work. Abstracts are not considered prior publication, but should be cited in the Acknowledgments section. Should there be a possibility of doubt concerning such prior publications, the title page and abstract of such material and of related manuscripts submitted for publication at other journals should be included with the submitted paper.

**Authors and Contributors:** With regard to authorship credit, ASN journals have adopted the criteria recommended by the International Committee of Medical Journal Editors (ICMJE) in the October 2005 update of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: "Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions

related to the accuracy or integrity of any part of the work are appropriately investigated and resolved." Note the full text of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (<http://www.icmje.org/>). In addition, with regard to contributors, ASN journals have adopted the following statement of editorial policy from the Information for Authors ([http://www.annals.org/shared/author\\_info.shtml](http://www.annals.org/shared/author_info.shtml)) of the *Annals of Internal Medicine*: "Medical writers and industry employees can be legitimate contributors, and their roles, affiliations, and potential conflicts of interest should be described when submitting manuscripts. These writers should receive acknowledgment on the byline or in the acknowledgments section in accord with the degree to which they contributed to the work reported in the manuscript. The Editors consider failure to acknowledge these contributors ghostwriting, and ghostwriting is unacceptable." Note that the ASN reserves the right to retract articles that do not meet the above criteria for authorship.

**Declaration of Helsinki:** For all clinical experimentation described in the manuscript, *JASN* requires that authors state in the Methods section their adherence to the *Declaration of Helsinki*. A statement that informed consent was obtained must also appear in the manuscript. For the full text of the *Declaration of Helsinki*, see <http://www.wma.net/en/30publications/10policies/b3/>.

**Declaration of Istanbul:** For all relevant transplant articles, *JASN* requires authors state in the Concise Methods section their adherence to the *Declaration of Istanbul*. For the full text of the *Declaration of Istanbul*, see <http://www.declarationofistanbul.org/>.

**Animal Experimentation:** For all animal experimentation described in the manuscript, *JASN* requires that authors state in the Methods section their adherence to the NIH Guide for the Care and Use of Laboratory Animals or the equivalent. For the full text of the NIH guidelines, see <http://grants.nih.gov/olaw/references/phsol.htm>.

**Statement of Financial Support:** Authors are required to divulge any relationships with pharmaceutical firms or other entities (such as employment contracts, consultancy, advisory boards, speaker bureaus, membership of Board of Directors, stock ownership) that could be perceived to represent a financial conflict of interest or to declare that no financial conflict of interest exists. Financial conflict of interest statements will be published at the end of the text of the article. If the authors have no conflicts, please state "Disclosures: None".

**Permission to Reprint Letters:** Letters granting permission to reprint must be included from the publisher and author of all previously printed or adapted material. These should be uploaded as Supporting Documents when the manuscript is submitted through Manuscript Central.

**Requirement for Registration of Clinical Trials:** The ASN requires, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we require registration by April 1,

2006, before considering the trial for publication. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials) are exempt. We do not advocate one particular registry, but registration must be with a registry that meets the following minimum criteria: accessible to the public at no charge, searchable by standard electronic (internet-based) methods, open to all prospective registrants free of charge or at minimal cost, validation of registered information, and identification of trials with a unique number. An acceptable registry also includes information on the investigator(s), the research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing, or closed), and funding source(s).

*Registries that currently meet these criteria include the following:*

The registry sponsored by the US National Library of Medicine ([www.clinicaltrials.gov](http://www.clinicaltrials.gov))  
 The International Standard Randomised Controlled Trial Number registry ([www.controlled-trials.com](http://www.controlled-trials.com))  
 The Cochrane Renal Group registry ([www.cochrane-renal.org/trialsubmissionform.php](http://www.cochrane-renal.org/trialsubmissionform.php))  
 The National (UK) Research Register ([www.update-software.com/national/](http://www.update-software.com/national/))  
 European Clinical Trials Database (<http://eudract.emea.eu.int/>)

**ASN Policy on Scientific Misconduct:** The American Society of Nephrology (ASN) journals uphold the highest standards of peer review and academic publishing. The work of authors and reviewers contributes to our common aim of understanding the latest advances in basic, clinical, and translational research. In very rare instances, editors receive notification or allegations of misconduct related to studies submitted to ASN journals, and our process for responding to such notification is detailed below.

#### **Concerns raised prior to publication:**

If a reviewer or a concerned co-author raises a question about a manuscript that is undergoing peer review and the Editor-in-Chief agrees, we will notify the author(s) and request a response to the reviewer's concerns. (Such concerns include but are not limited to questions regarding plagiarism, duplicate publication, access to data, and integrity of data or undeclared conflicts of interest.) In most instances these concerns are readily addressed and resolved and involve honest errors or differences in interpretation rather than any intent to deceive.

If the authors do not respond satisfactorily (or at all) to the concerns raised, or if the Editor-in-Chief is presented with evidence that indicates serious concerns regarding the conduct of the study, the Editor-in-Chief will notify the Chair of the Publications Committee and will determine a course of action, in part determined by applicable laws, which may include any or all of the following:

- a. rejecting the manuscript; and/or
- b. prohibiting future submissions from the authors of the manuscript for a specified period of time;
- c. obtaining an advisory opinion from the Committee on Publication Ethics (COPE);
- d. reporting their concerns to the authors' institutions
- e. reporting their concerns to the funding agency
- f. reporting their concerns to the Office of Research Integrity or other authorized investigative agency.

If the matter has been deemed serious enough to warrant the attention of the Publications Committee, the Publications Chair will keep the ASN President informed of all developments.

#### **Concerns raised subsequent to electronic and/or print publication:**

If questions are raised by a reader regarding a published study, and the Editor-in-Chief agrees, the journal will notify the author(s) and request a response to the stated concerns. (Such concerns include but are not limited to questions regarding plagiarism, duplicate publication, access to data, and integrity of data or undeclared conflicts of interest.) In most instances these concerns are readily resolved and involve honest errors or differences in interpretation rather than any intent to deceive.

If the authors do not respond satisfactorily (or at all) to the concerns raised, or if the editors are presented with evidence that indicates serious concerns regarding the conduct of the study, the Editor-in-Chief will notify the Chair of the Publications Committee and determine a course of action, in part determined by applicable laws, which may include any or all of the following:

- a. reporting their concerns to the authors' institutions;
- b. prohibiting future submissions from the authors of the manuscript for a specified period of time;
- c. obtaining an advisory opinion from the Committee on Publication Ethics (COPE);
- d. reporting their concerns to the funding agency;\*
- e. reporting their concerns to the Office of Research Integrity or other authorized investigative agency;\*
- f. publishing a statement of concern in the journal;
- g. issuing a retraction;
- h. notifying any other publication involved (in the case of duplicate publication or plagiarism).

If the matter has been deemed serious enough to warrant the attention of the Publications Committee, the Publications Chair will keep the ASN President informed of all developments.

#### **ADDITIONAL ITEMS OF NOTE**

**DNA Arrays:** Now that DNA array technology has become established in renal research, JASN will review only papers in which the initial results of array analysis have been extended to either identify or characterize a new gene of interest or to analyze the functional significance of known genes observed in the data set. Reports that contain only screening data on all genes found to be up- or downregulated under a particular circumstance will not be considered for publication except under unusual circumstances.



**Studies of DNA Polymorphisms:** For population-based case-control studies describing an association between a DNA polymorphism and renal disease, in addition to insuring adequate sample size, appropriate correction of *P* values for multiple comparisons (*P* values must be rounded to two decimal places as applicable), and findings that “make sense” biologically, *JASN* will usually require one of the following for papers to be considered for publication: data showing an effect of the polymorphism on protein function or gene expression; confirmation of the association using a family-based method, *eg.* transmission-disequilibrium; replication of the association in an independent sample; or measurement of and correction for population stratification in the samples. Moreover, recent studies indicate that the haplotype structure of the human genome is relatively limited. The genome has been depicted as a series of regions of high linkage disequilibrium (haplotype blocks), each with limited diversity, separated by sites of recombination. A particular SNP may be shared by several common haplotypes, of which only one is associated with a disease. It is not possible to identify this “risk haplotype” by genotyping a single SNP. Therefore, special consideration will be given to studies in which haplotype analysis is used to identify the “risk haplotype” associated with a renal disease.

**Randomized Controlled Trials:** *JASN* now encourages authors submitting reports of randomized controlled trials to review the CONSORT Statement (<http://www.consort-statement.org/>). The CONSORT Statement includes recommendations, a checklist of items that should be included in a comprehensive report, and a participant flow diagram. Reports of randomized controlled trials that do not conform to the CONSORT guidelines may be returned to authors for revision prior to formal review.

Authors preparing reports of randomized clinical trials are encouraged to consult the CONSORT checklist (<http://www.consort-statement.org/index.aspx?o=2965>) and to include a CONSORT flow diagram (<http://www.consort-statement.org/consort-statement/flow-diagram0/>) as a figure in the manuscript. Authors of observational studies are encouraged to consult the STROBE checklists (<http://www.strobe-statement.org/>).

## MANUSCRIPT SUBMISSION

All manuscripts must be submitted online at <http://mc.manuscriptcentral.com/jasn>. The corresponding author must have e-mail access. From <http://jasn.asnjournals.org/>, click on “Online Submission.” Type your existing login/password, or click on “Create an Account.” Be careful not to create more than one account for yourself. Whether you are submitting a manuscript or reviewing a manuscript, you will use the same account information. You may make changes to the account at any time. Click on Author and follow the instructions. If at any time during the online submission process you have a question or need help, click on Help in the upper right hand corner.

Manuscripts should be typed in English and double-spaced with line numbers and page numbers. The title should be less than 10 words; all authors’ full names (first name, middle initial and last name); highest academic degrees and affiliations; the name, address, telephone and fax number, and e-mail address of the corresponding author; a running title; and key words. The word

count for the abstract and the word count for the text, excluding references, figures and tables should also be included.

For editorial questions, call 202-697-2068 or email [bobrien@asn-online.org](mailto:bobrien@asn-online.org).

## FIGURES

Figure legends should use only common abbreviations that do not require definition in the text. Figures must be cited in the text, in numerical order using Arabic numerals. Authors are responsible for the cost of color pages. Figures submitted and reviewed as color will be printed in color (\$600/page).

Authors of accepted manuscripts must provide figures in one of the following formats: EPS, AI, TIFF, PDF, or Microsoft Office. Raster (pixel-based) images should be produced at appropriate resolution: 1200 dpi for black and white images in bitmap mode such as graphs and log scales, 600 dpi for grayscale or color combination images such as gels or blots combined with text or line-art, and 300 dpi for regular grayscale or color images without text or line-art combined. Please be sure to use high resolution and maximum quality compression settings if creating PDFs.

### Graphic Preparation Guidelines:

1. Figures that are similar in appearance should be created to look uniform (e.g., bar graphs, the bars should be the same width for all figures).
2. 1 column figures: create with a width of 14p6 (6.1 cm or 2.4 inches) to 20p6 (8.7 cm or 3.4 inches).
3. 2 column figures: create with a width between 30p (12.7 cm or 5 inches) and 42p3 (17.9 cm or 7 inches).
4. The type within the figure should be set in 6 pt type, using fonts of Times Roman, Helvetica, Arial, Symbol, Mathematical Pi, or European Pi.
5. Figure labels should be set 10 pt Helvetica, Bold caps, upper left corner.
6. If providing a multipart figure, space between parts should be 1 pica (0.42 cm or 0.167 inches) space.
7. When submitting line shots, submit as vector .eps figures whenever possible.
8. Symbols must be consistent when representing the same thing across all figures (e.g., different symbols must be used to represent different *P* values).
9. Multipanel figures must be provided as a single composite file.
10. Color images should be saved in RGB mode with ICC profiles embedded if possible.

Please read our Digital Art Guidelines for more specific instructions. Click on Author Resources on the *JASN* website ([www.jasn.asnjournals.org](http://www.jasn.asnjournals.org)).

## REFERENCE FORMATS

References should be listed in order of their appearance in the text. Please adhere to the reference limit for each type of article. List all authors for each article cited (do not use *et al.*). Journal names should be abbreviated according to the MEDLINE list of serials. Superscripted numbers in the text should be used to indicate references; these superscripted numbers must be placed immediately after a comma or period if cited at the end of a phrase or sentence.

### Example journal articles, books, and abstracts:

1. Nangaku M, Pippin J, Couser WG: Complement membrane attack complex (C5b9) mediates interstitial disease in experimental nephrotic syndrome. *J Am Soc Nephrol* 10: 2323–2332, 1999

2. May RC, Mitch WE: Pathophysiology of uremia. In: *The Kidney*, 5th ed., edited by Brenner BM, Philadelphia, WB Saunders, 1996, pp 2148–2169
3. Yoo KH, Norwood VF, Chevalier RL: Regulation of angiotensin II AT1 and AT2 receptors in neonatal unilateral ureteral obstruction [Abstract]. *J Am Soc Nephrol* 6: 1035, 1995

## REVISIONS

If you received a decision letter that indicated we would be interested in a revised version of the paper, click on Author, then click on Manuscripts with Decisions. You can then click on Create a Revision on the specific manuscript. Please upload a clean version of the revised paper and also a version that indicates the changes from the original version.

## ACCEPTED MANUSCRIPTS

After a manuscript has been accepted for publication, the authors will need to upload a final set of files as a revised manuscript. The text and tables will need to be sent as a Word document (one file) and each figure in one of the following formats: EPS, AI, TIFF, PDF, or Microsoft Office. Supplemental information should be submitted in one pdf file.

JASN submits, on behalf of its authors, all articles directly to PubMed Central, where they will be freely available within 12 months of publication.

## AUTHOR CHOICE

Authors may choose to have the digital posting of his/her manuscript freely accessible as soon as the issue is posted online through a program called, “Author Choice.” The “Author Choice” flat fee to make an author’s manuscript openly accessible when the issue is posted online is \$3000, which must be prepaid before the manuscript can be made accessible. Authors will have the opportunity to make this choice when page proofs and invoice are received.

## PICTURES FOR THE FRONT COVER

The Editors welcome the submission of high-resolution cover photographs from authors of accepted manuscripts. To submit your image, please go to <http://www.jasn.org>, click on “Submit Manuscripts Online,” and select manuscript type “Unsolicited Feature/Cover Image.” Please upload the possible figure and the legend as separate files. Please note the manuscript number of the related accepted paper.

## PROOFS

Manuscripts will be copyedited, and electronic proofs will be made available for author approval. Authors will be notified by

email when their proofs are ready. Download, read, correct using annotations, and upload the corrected proofs within 48 hours. Papers containing clinical information will not be published unless authors have approved the galley proofs. Be sure that all editor or printer queries are answered. Only minor corrections are permitted. Changes to figures at proof stage will not be allowed except in rare cases when the original figure does not show the needed detail when converted. Authors will need to check co-authors names and affiliations carefully at proof stage. **Changes will not be made after the paper has posted online.**

## PUBLICATION FEES

**Page Charges:** Authors will be charged \$70.00 per manuscript page.

**Color Charges:** Authors will be charged \$600.00 per color page. (Figures submitted in color will be published in color.) Within 48 hours of proof, you will receive an email from aubilling.djs@sheridan.com with a link to our online billing and reprint ordering system. You must log in to this site to review your publication charge estimate and provide payment information for all applicable charges (purchase order or credit card information). You will also have the opportunity to order reprints at this stage. If you have any questions regarding the estimate or ordering reprints, please contact aubilling.djs@sheridan.com or call 802-560-8518.

Invited submissions and editorials will be exempt from these charges.

Pricing includes the purchase of reprints by the author(s) for personal use only. Non-authors can purchase reprints *via* Sheridan Content Services. Contact Hope Robinson at 800-635-7181, ext. 8065, or email [hope.robinson@sheridan.com](mailto:hope.robinson@sheridan.com).

## DISCLAIMER

The statements and opinions contained in the articles of JASN are solely those of the individual authors and contributors and not of the American Society of Nephrology. The appearance of advertisements in the Journal is not a warranty, endorsement, or approval of the products or services advertised or of their safety. The American Society of Nephrology and the Publisher disclaim responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.